Press Release | Tissuepathology.com

Proscia to Collaborate with Columbia University on Biomarker Discovery for Neurodegenerative Diseases

Erica Goodpaster — Wed, 28 Oct 2026 12:51:31 +0000

Philadelphia – October 27, 2026 – Proscia has entered into a collaborative agreement with Columbia University to identify biomarkers for neurodegenerative diseases, such as Alzheimer’s and other dementias. The collaboration pairs Columbia’s pathology leadership and digital slide repository with Proscia’s deep pathology AI expertise. “Collaborating with Proscia will enable us to leverage numerous data streams […]

The post Proscia to Collaborate with Columbia University on Biomarker Discovery for Neurodegenerative Diseases first appeared on Tissuepathology.com.

Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development

Erica Goodpaster — Mon, 26 Oct 2026 12:38:46 +0000

Lunit and Summit Therapeutics: Research Will Use Lunit’s AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology Seoul, South Korea and Miami, Florida, October 23, 2026 – Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a research agreement to evaluate the use of Lunit […]

The post Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development first appeared on Tissuepathology.com.

SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment

Erica Goodpaster — Thu, 22 Oct 2026 16:42:29 +0000

SimBioSys: Novel software transforms routinely collected MRI, pathology and clinical data into personalized five- and ten-year recurrence risk insight for women with early-stage breast cancer CHICAGO, IL – October 15, 2026 – SimBioSys®, an AI-driven precision medicine company revolutionizing how cancer is understood and treated, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance […]

The post SimBioSys Secures FDA Clearance for TumorSight® Risk, Introducing the World’s First AI-Powered, MRI-Derived Breast Cancer Recurrence Risk Assessment first appeared on Tissuepathology.com.

HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases

Erica Goodpaster — Tue, 20 Oct 2026 12:52:38 +0000

[SINGAPORE, October 19th, 2026] – /PR Newswire/ HistoIndex, a pioneer in AI-driven digital pathology for fibrotic diseases, and the Agency for Science, Technology and Research (A*STAR), Singapore’s lead public sector R&D agency, have signed a Memorandum of Understanding (MoU) to collaborate on the preclinical evaluation and characterization of therapeutic candidates for various fibrotic diseases, including […]

The post HistoIndex and A*STAR Partner To Advance Early – Stage Development Of Pipeline Therapies For Fibrotic Diseases first appeared on Tissuepathology.com.

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

Erica Goodpaster — Mon, 19 Oct 2026 12:41:31 +0000

Tempus: Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images CHICAGO–(BUSINESS WIRE)–Tempus AI, Inc. (NASDAQ: TEM) today announced results from a study evaluating an AI-enabled pre-screening panel for patients with advanced non-small cell lung cancer (NSCLC). The panel […]

The post Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC first appeared on Tissuepathology.com.

Indica Labs and NeoGenomics Expand AI Leadership Through Enterprise Digital Pathology Partnership

Erica Goodpaster — Fri, 16 Oct 2026 11:41:44 +0000

ALBUQUERQUE, N.M, October 15, 2026 — Indica Labs, the trusted global leader in AI-powered digital pathology, today announced a significant expansion of its strategic partnership with NeoGenomics, a leading provider of oncology diagnostic solutions that enable precision medicine. The expanded collaboration is intended to modernize NeoGenomics enterprise digital pathology infrastructure, accelerate the evaluation and adoption […]

The post Indica Labs and NeoGenomics Expand AI Leadership Through Enterprise Digital Pathology Partnership first appeared on Tissuepathology.com.